Do GLP-1 drugs like Ozempic prevent cancer? – Image for illustrative purposes only (Image credits: Pixabay)
Medications known as GLP-1 receptor agonists, including popular brands like Ozempic and Wegovy, have transformed treatment for diabetes and obesity. As their use surges worldwide, researchers have turned attention to an intriguing side benefit: potential protection against certain cancers. Multiple large-scale studies published in recent years indicate these drugs may lower the odds of developing obesity-related malignancies, sparking interest among oncologists and public health experts.
Key Studies Reveal Protective Effects
Investigators analyzed vast patient databases to compare cancer outcomes among those taking GLP-1 drugs versus alternatives like insulin or other therapies. One comprehensive review of patients with type 2 diabetes found that GLP-1 receptor agonists linked to lower incidence of 10 out of 13 obesity-associated cancers.[1] Another examination showed these medications reduced overall cancer risk, with particularly strong signals for endometrial, ovarian, and colorectal tumors.[2]
Researchers also explored first-generation GLP-1s such as liraglutide, exenatide, and dulaglutide. Their analysis determined these drugs proved 41% more effective at preventing obesity-related cancers than expected from weight loss alone.[3] Even in comparisons with DPP-4 inhibitors, GLP-1 users faced modestly lower rates of 14 such cancers, especially colorectal.[4] These findings emerged from observational data spanning millions of records, offering real-world insights into long-term use.
Cancers Most Affected by GLP-1 Use
Obesity drives heightened risk for at least 13 cancer types, from breast to liver. Studies consistently flagged colorectal cancer as a standout beneficiary, with GLP-1 therapy slashing incidence by up to a third in some cohorts.[5] Endometrial and ovarian cancers also showed substantial drops, alongside reductions in pancreatic, liver, and gastric cases.
- Colorectal: Up to 33% lower risk versus controls.
- Endometrial: Notable hazard ratio reductions in multiple analyses.
- Ovarian and meningioma: Significant protective associations.
- Breast (postmenopausal): Mixed but often favorable outcomes.
- Lung and prostate: Emerging signals of benefit.
One cohort tracked adults with overweight or obesity over years. Those on GLP-1s experienced 17% lower overall cancer rates compared to non-users.[6] Benefits held across diabetes status and body weight categories, suggesting broader applicability.
Beyond Weight Loss: Direct Anti-Cancer Actions?
Weight reduction explains much of the effect, given obesity’s role in fueling inflammation and hormone imbalances that promote tumors. Yet lab work hints at more. In obese mice, GLP-1 drugs slowed breast tumor growth even on high-fat diets, restoring immune vigilance against cancer cells.[7]
Cell studies support this: GLP-1s inhibited cancer cell proliferation, induced cell death, and altered tumor environments.[8] Colon cancer patients on these drugs showed dramatically lower death rates, per UC San Diego research.[8] Early human data from breast cancer trials echoed improvements in chemotherapy tolerance and survival.[9]
Key Takeaways: GLP-1s appear safe regarding cancer incidence, with meta-analyses confirming no overall risk increase and potential reductions in obesity-linked types.
Unresolved Concerns and Future Directions
Not all data aligned perfectly. A December 2025 analysis concluded GLP-1s had little or no effect on obesity-related cancer risks, urging longer trials.[10][11] Thyroid cancer worries stemmed from rodent studies, prompting warnings against use in those with family history of medullary thyroid cancer.[12] Kidney cancer hints surfaced in one review, though unconfirmed.[13]
Most evidence remains observational, lacking randomized controlled trials for cancer endpoints. Experts call for sustained monitoring as prescriptions climb. Still, the trajectory favors these drugs as allies in tackling obesity’s cancer toll. Patients should discuss personal risks with providers, especially amid evolving evidence.
As research accelerates into 2026, GLP-1 agonists stand poised to redefine prevention strategies for weight-driven diseases.